2017
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model
Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLOS Medicine 2017, 14: e1002202. PMID: 28045934, PMCID: PMC5207633, DOI: 10.1371/journal.pmed.1002202.Peer-Reviewed Original ResearchConceptsEase of adherenceTB mortalityTB incidenceNovel drug regimensTB regimenNovel regimenDrug regimensRegimen characteristicsTreatment durationTreatment efficacyRR-TB treatmentTB treatment efficacyRifampicin-resistant TBTB treatment durationDynamic transmission modelTB regimensNew regimensRR-TBTB treatmentMedical contraindicationsPatients' qualitySafety profileBaseline prevalenceTB epidemicTuberculosis treatment
2014
Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling
Dowdy DW, Houben R, Cohen T, Pai M, Cobelens F, Vassall A, Menzies NA, Gomez GB, Langley I, Squire SB, White R, for the TB MAC meeting participants. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 1012-1018. PMID: 25189546, PMCID: PMC4436823, DOI: 10.5588/ijtld.13.0851.Peer-Reviewed Original ResearchDrivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis
Shrestha S, Knight GM, Fofana M, Cohen T, White RG, Cobelens F, Dowdy DW. Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis. Open Forum Infectious Diseases 2014, 1: ofu073. PMID: 25734143, PMCID: PMC4281792, DOI: 10.1093/ofid/ofu073.Peer-Reviewed Original ResearchDrug-resistant TBTreatment of tuberculosisNew drug regimenTransmission fitnessDrug regimensDrug regimenTreatment successDrug-susceptible TBAppropriate second-line therapyDR-TB prevalenceSecond-line therapyDrug resistance trendsTreatment success rateHigher treatment successNovel drug regimensEmergence of resistancePopulation-level dataTB regimensShort-term surveillanceDS-TBNew regimenClinical trialsEarly diagnosisRegimensDrug resistance